What are the regional growth trends and the largest revenue-generating regions for biochips market?
The overall biochips market is estimated to grow at a CAGR of 18.4% from 2015 to 2020 to reach $17.75 billion by 2020.
The biochips market is divided into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2015, North America is expected to account for the largest share of this market, followed by Europe. Factors such as increasing aging population and rising prevalence of lifestyle diseases and cardiac disorders are the key drivers for the growth of the North American biochips market
On the other hand, the market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Rapid growth in the life sciences industry in China and India, growth in biotechnology and pharmaceutical research, and low infrastructure costs are some major factors driving the growth of the biochips market in Asia
Request FREE Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=54
Who are the major market players in the biochips market?
Abbott Laboratories (US), Agilent Technologies, Inc. (US), PerkinElmer Inc. (US), Fluidigm Corporation (US), Illumina, Inc. (US), GE Healthcare (US), Bio-Rad Laboratories Inc. (US), Cepheid Inc. (US), Thermo Fisher Scientific, Inc. (US), and F. Hoffmann-La Roche AG (Switzerland).
Thermo Fisher Scientific is among the leaders in the biochips market, with a strong presence in different locations across the globe. The company marked its leadership position through the acquisition of Affymetrix Inc., the first company to commercialize DNA microarrays. Through this acquisition, Affymetrix added complementary products in genetic analysis, which are used in cytogenetics, genotyping, and gene expression, to the company’s life sciences portfolio.
Also get information about:-
Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of various other dependent submarkets. The fabrication technology markets for all segments were determined through secondary research and were added up to obtain the global market value.
Secondary research included the study of the annual and financial reports of top market players, whereas primary research included extensive interviews with the key opinion leaders such as CEOs, directors, and marketing executives. The percentage splits, shares, and breakdowns of the product markets were determined using secondary sources and verified through primary sources.
This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Some of the secondary resources we referred are U.S. Food and Drug Administration, Journal of Biochips & Tissue Chips, American Medical Association (AMA), National Cancer Institute, Journal of Molecular Diagnostic and The World Bank.
The overall biochips market is estimated to grow at a CAGR of 18.4% from 2015 to 2020 to reach $17.75 billion by 2020.
The biochips market is divided into four major regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2015, North America is expected to account for the largest share of this market, followed by Europe. Factors such as increasing aging population and rising prevalence of lifestyle diseases and cardiac disorders are the key drivers for the growth of the North American biochips market
On the other hand, the market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. Rapid growth in the life sciences industry in China and India, growth in biotechnology and pharmaceutical research, and low infrastructure costs are some major factors driving the growth of the biochips market in Asia
Request FREE Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=54
Who are the major market players in the biochips market?
Abbott Laboratories (US), Agilent Technologies, Inc. (US), PerkinElmer Inc. (US), Fluidigm Corporation (US), Illumina, Inc. (US), GE Healthcare (US), Bio-Rad Laboratories Inc. (US), Cepheid Inc. (US), Thermo Fisher Scientific, Inc. (US), and F. Hoffmann-La Roche AG (Switzerland).
Thermo Fisher Scientific is among the leaders in the biochips market, with a strong presence in different locations across the globe. The company marked its leadership position through the acquisition of Affymetrix Inc., the first company to commercialize DNA microarrays. Through this acquisition, Affymetrix added complementary products in genetic analysis, which are used in cytogenetics, genotyping, and gene expression, to the company’s life sciences portfolio.
Also get information about:-
- What are the major product segments in the biochips market?
- What are the major drivers and challenges in the biochips market?
- What are the major end users for biochips?
Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of various other dependent submarkets. The fabrication technology markets for all segments were determined through secondary research and were added up to obtain the global market value.
Secondary research included the study of the annual and financial reports of top market players, whereas primary research included extensive interviews with the key opinion leaders such as CEOs, directors, and marketing executives. The percentage splits, shares, and breakdowns of the product markets were determined using secondary sources and verified through primary sources.
This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. Some of the secondary resources we referred are U.S. Food and Drug Administration, Journal of Biochips & Tissue Chips, American Medical Association (AMA), National Cancer Institute, Journal of Molecular Diagnostic and The World Bank.
Comments
Post a Comment